Trials / Recruiting
RecruitingNCT07118241
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Lubris Bio Pty Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
rhPRG4-Sjögren's-002 is a prospective multi-center study conducted in Australia to evaluate the safety and efficacy of topically-applied rhPRG4 in subjects with Sjögren's related Dry Eye Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Recombinant Human Proteoglycan 4 | rhPRG4 450ug/ml |
| DRUG | Vehicle Control | PBS based Vehicle Conrtol |
Timeline
- Start date
- 2025-09-17
- Primary completion
- 2026-07-30
- Completion
- 2026-08-01
- First posted
- 2025-08-12
- Last updated
- 2026-02-05
Locations
6 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT07118241. Inclusion in this directory is not an endorsement.